TRANSGENE Reports 2014 Financial Results And Outlines Promising Clinical Pipeline
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene SA (Paris:TNG) (Euronext: TNG) today announced its financial results for the fiscal year ended December 31, 2014 and provided a business update.
Clinical highlights include:
•Two Phase 3 trials in preparation for TG4010 and Pexa-Vec
Help employers find you! Check out all the jobs and post your resume.
Transgene SA (Paris:TNG) (Euronext: TNG) today announced its financial results for the fiscal year ended December 31, 2014 and provided a business update.
Clinical highlights include:
•Two Phase 3 trials in preparation for TG4010 and Pexa-Vec
Help employers find you! Check out all the jobs and post your resume.